Not real patients

A CLEAR CHOICE

For rapid acne reduction that helps prevent acne scarring and improves PIH†1-3abcd

A comprehensive approach to acne management

AKLIEF Cream is the first and only RAR-γ*, FDA approved topical retinoid that rapidly reduces acne and helps manage acne sequelae.2,3ab  Its powerful and precise mechanism helps address both active acne and its long-term consequences, supporting meaningful improvements in the outcomes that matter most to patients.5,6

Evolved targeting specificity

AKLIEF Cream is the first topical retinoid therapy to utilize trifarotene, a fourth generation retinoid that selectively targets RAR-γ. This targeted mechanism delivers a precise and powerful therapeutic effect.4,7

Discover how AKLIEF Cream addresses acne through its unique mechanism of action and the science that supports it.

Learn How It Works

Addressing acne and its lasting impacts

AKLIEF Cream has been shown to help rapidly reduce acne on the face and trunk, reducing the risk of acne scarring, and improving atrophic acne scars and post-inflammatory hyperpigmentation (PIH).1,2,3abcd See what improvement could look like for your patients.

Explore the Evidence See Real Results

Supporting patients from day one

Set patients up for success with AKLIEF Cream by exploring resources on treatment initiation, patient education, long-term safety and tolerability, and strategies to support adherence throughout the treatment journey.8

Learn About Tolerability Find Resources
""
Not a real patient
Not a real doctor

Stay connected with AKLIEF Cream

Sign up to receive the latest AKLIEF Cream updates, including clinical data, educational resources, patient support tools, and product information to help optimize acne care.

Stay Informed
About AKLIEF Cream

*RAR, retinoic acid receptor

†PIH, post-inflammatory hyperpigmentation

a. Studied in acne patients from 9 to 58 years of age with diverse skin types and moderate-to-severe acne. Nodulocystic acne was excluded from the trials.

b. Significant improvement in inflammatory and noninflammatory lesions seen as early as Week 1 in the pivotal clinical trials.

c. Secondary to clearing acne.

d. The primary endpoint was the overall disease severity score (ODS). No statistically significant difference between AKLIEF Cream and vehicle at Week 24 was seen.

References

  1. Tan J, Thiboutot D, Popp G, et al. Randomized Phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–1699.
  2. Schleicher S, Moore A, Rafal E, et al. Trifarotene reduces risk for atrophic acne scars: results from a Phase 4 controlled study. Dermatol Ther (Heidelb). 2023;13(12):3085–3096.
  3. Alexis A, et al. Efficacy and safety of trifarotene 50 μg/g cream in acne-induced post-inflammatory hyperpigmentation. Int J Dermatol. 2024;63(6):806–815.
  4. Aubert J, et al. Trifarotene: development of a potent and selective RAR-γ agonist for topical treatment of acne. Br J Dermatol. 2018;179(2):442–456.
  5. Layton A, et al. JAAD Int. 2021;5:41–48.
  6. Darji K, et al. J Clin Aesthet Dermatol. 2017;10(5):18–23.
  7. Thoreau E, et al. Bioorg Med Chem Lett. 2018;28(10):1736–1741.
  8. Blume-Peytavi U, Fowler J, Kemény L, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166–173.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.